Showing 121 - 140 results of 543 for search '"virus"', query time: 0.06s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124

    Nucleic Acid Aptamers for Human Norovirus GII.4 and GII.17 Virus-Like Particles (VLPs) Exhibit Specific Binding and Inhibit VLPs from Entering Cells by Cheng C, Sun M, Li J, Xue Y, Cai X, Liu J, Wang X, Xu S, Xie Y, Zhang J

    Published 2025-02-01
    “…Here, we screened nucleic acid aptamers against the widespread HuNoV GII.4 and emerging HuNoV GII.17.Methods: After ten rounds of sieving for HuNoV GII.4 and GII.17 virus-like particles (VLPs), eight ssDNA aptamers were generated and characterized for each genotype.Results: Four of the eight aptamers generated for GII.4 VLP had dissociation constants (Kd) less than 100 nM, and all aptamers for GII.17 VLP had Kd less than 10 nM. …”
    Get full text
    Article
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132

    The role of new hepatitis B vaccines in South Africa by G U van Zyl, T Maponga, H Rabie, J Taljaard

    Published 2024-02-01
    Subjects: “…Hepatitis B virus…”
    Get full text
    Article
  13. 133
  14. 134

    AAV-based vectors for human diseases modeling in laboratory animals by Timur I. Aliev, Dmitry V. Yudkin

    Published 2025-02-01
    Subjects: “…adeno-associated virus…”
    Get full text
    Article
  15. 135
  16. 136
  17. 137

    Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

    Published 2025-02-01
    “…IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX), and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting.MethodsUsing the EMBASE, PubMed, and Cochrane Library databases, articles were screened from 1 January 2016 to 1 June 2024. …”
    Get full text
    Article
  18. 138
  19. 139
  20. 140